Kannabinoidireseptori (Finnish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Kannabinoidireseptori" in Finnish language version.

refsWebsite

Global rank Finnish rank

28nih.gov

4^th place

12^th place

17worldcat.org

5^th place

9^th place

16doi.org

2^nd place

10^th place

1guidetopharmacology.org

low place

1tandfonline.com

507^th place

559^th place

1ashdin.com

low place

1wiley.com

222^nd place

202^nd place

1semanticscholar.org

11^th place

2,329^th place

1sciencedirect.com

149^th place

237^th place

ashdin.com

ES Onaivi et al: Cannabinoid receptor gene variations in drug addiction and neuropsychiatric disorders. Journal of Drug and Alcohol Research, 2013, 2. vsk, s. 1–11. doi:10.4303/jdar/235714. ISSN 2090-8334. Artikkelin verkkoversio.

doi.org

dx.doi.org

MR Elphick: The evolution and comparative neurobiology of endocannabinoid signalling. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367. vsk, nro 1607, s. 3201–3215. PubMed:23108540. doi:10.1098/rstb.2011.0394. ISSN 0962-8436. Artikkelin verkkoversio.
DI Abrams: Integrating cannabis into clinical cancer care. Current Oncology, 2016, 23. vsk, nro Suppl 2, s. S8–S14. PubMed:27022315. doi:10.3747/co.23.3099. ISSN 1198-0052. Artikkelin verkkoversio.
L Fattore, W Fratta: Beyond THC: the new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 2011, 5. vsk. PubMed:22007163. doi:10.3389/fnbeh.2011.00060. ISSN 1662-5153. Artikkelin verkkoversio.
DR Janero, A Makriyannis: Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs, 2009, 14. vsk, nro 1, s. 43–65. PubMed:19249987. doi:10.1517/14728210902736568. ISSN 1744-7623. Artikkelin verkkoversio.
S Zou, U Kumar: Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International Journal of Molecular Sciences, 2018, 19. vsk, nro 3. PubMed:29533978. doi:10.3390/ijms19030833. ISSN 1422-0067. Artikkelin verkkoversio.
S Basu, BN Dittel: Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunologic research, 2011, 51. vsk, nro 1, s. 26–38. PubMed:21626285. doi:10.1007/s12026-011-8210-5. ISSN 0257-277X. Artikkelin verkkoversio.
ES Onaivi et al: Cannabinoid receptor gene variations in drug addiction and neuropsychiatric disorders. Journal of Drug and Alcohol Research, 2013, 2. vsk, s. 1–11. doi:10.4303/jdar/235714. ISSN 2090-8334. Artikkelin verkkoversio.
M Haney, MN Hill: Cannabis and cannabinoids: from synapse to society. Neuropsychopharmacology, 2018, 43. vsk, nro 1, s. 1–3. PubMed:29192667. doi:10.1038/npp.2017.255. ISSN 1740-634X. Artikkelin verkkoversio.
PH Reggio: Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Current medicinal chemistry, 2010, 17. vsk, nro 14, s. 1468–1486. PubMed:20166921. doi:10.2174/092986710790980005. ISSN 0929-8673. Artikkelin verkkoversio.
RG Pertwee: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 2008, 153. vsk, nro 2, s. 199–215. PubMed:17828291. doi:10.1038/sj.bjp.0707442. ISSN 0007-1188. Artikkelin verkkoversio.
C Hess et al: Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicology, 2016, 34. vsk, s. 329–343. PubMed:27429655. doi:10.1007/s11419-016-0320-2. ISSN 1860-8965. Artikkelin verkkoversio.
I Canazza et al: Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. Human Psychopharmacology, 2017, 32. vsk, nro 3. PubMed:28597570. doi:10.1002/hup.2601. ISSN 1099-1077. Artikkelin verkkoversio.
JA Marusich et al: Finding order in chemical chaos - continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology, 2018, 134. vsk, nro Pt A, s. 73–81. PubMed:29113898. doi:10.1016/j.neuropharm.2017.10.041. ISSN 0028-3908. Artikkelin verkkoversio.
RF Porter et al: Selective cannabinoid 2 receptor agonists as potential therapeutic drugs for the treatment of endotoxin-induced uveitis. Molecules, 2019, 24. vsk, nro 18. PubMed:31540271. doi:10.3390/molecules24183338. ISSN 1420-3049. Artikkelin verkkoversio.
MM Aung et al: Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug and Alcohol Dependence, 2000, 60. vsk, nro 2, s. 133–140. PubMed:10940540. doi:10.1016/s0376-8716(99)00152-0. ISSN 0376-8716. Artikkelin verkkoversio.
JA Lile, TH Kelly, LR Hays: Separate and combined effects of the cannabinoid agonists nabilone and Δ9-THC in humans discriminating Δ9-THC. Drug and alcohol dependence, 2011, 116. vsk, nro 1-3, s. 86–92. PubMed:21227600. doi:10.1016/j.drugalcdep.2010.11.019. ISSN 0376-8716. Artikkelin verkkoversio.

guidetopharmacology.org

GPR18, GPR55 and GPR119 | G protein-coupled receptors | IUPHAR/BPS Guide to PHARMACOLOGY guidetopharmacology.org. Viitattu 14.2.2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

MR Elphick: The evolution and comparative neurobiology of endocannabinoid signalling. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367. vsk, nro 1607, s. 3201–3215. PubMed:23108540. doi:10.1098/rstb.2011.0394. ISSN 0962-8436. Artikkelin verkkoversio.
DI Abrams: Integrating cannabis into clinical cancer care. Current Oncology, 2016, 23. vsk, nro Suppl 2, s. S8–S14. PubMed:27022315. doi:10.3747/co.23.3099. ISSN 1198-0052. Artikkelin verkkoversio.
L Fattore, W Fratta: Beyond THC: the new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 2011, 5. vsk. PubMed:22007163. doi:10.3389/fnbeh.2011.00060. ISSN 1662-5153. Artikkelin verkkoversio.
DR Janero, A Makriyannis: Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs, 2009, 14. vsk, nro 1, s. 43–65. PubMed:19249987. doi:10.1517/14728210902736568. ISSN 1744-7623. Artikkelin verkkoversio.
S Zou, U Kumar: Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International Journal of Molecular Sciences, 2018, 19. vsk, nro 3. PubMed:29533978. doi:10.3390/ijms19030833. ISSN 1422-0067. Artikkelin verkkoversio.
S Basu, BN Dittel: Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunologic research, 2011, 51. vsk, nro 1, s. 26–38. PubMed:21626285. doi:10.1007/s12026-011-8210-5. ISSN 0257-277X. Artikkelin verkkoversio.
M Haney, MN Hill: Cannabis and cannabinoids: from synapse to society. Neuropsychopharmacology, 2018, 43. vsk, nro 1, s. 1–3. PubMed:29192667. doi:10.1038/npp.2017.255. ISSN 1740-634X. Artikkelin verkkoversio.
PH Reggio: Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Current medicinal chemistry, 2010, 17. vsk, nro 14, s. 1468–1486. PubMed:20166921. doi:10.2174/092986710790980005. ISSN 0929-8673. Artikkelin verkkoversio.
RG Pertwee: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 2008, 153. vsk, nro 2, s. 199–215. PubMed:17828291. doi:10.1038/sj.bjp.0707442. ISSN 0007-1188. Artikkelin verkkoversio.
C Hess et al: Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicology, 2016, 34. vsk, s. 329–343. PubMed:27429655. doi:10.1007/s11419-016-0320-2. ISSN 1860-8965. Artikkelin verkkoversio.
I Canazza et al: Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. Human Psychopharmacology, 2017, 32. vsk, nro 3. PubMed:28597570. doi:10.1002/hup.2601. ISSN 1099-1077. Artikkelin verkkoversio.
JA Marusich et al: Finding order in chemical chaos - continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology, 2018, 134. vsk, nro Pt A, s. 73–81. PubMed:29113898. doi:10.1016/j.neuropharm.2017.10.041. ISSN 0028-3908. Artikkelin verkkoversio.
SMR Gurney et al: Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Science Review, 2014, 26. vsk, nro 1, s. 53–78. PubMed:26226970. ISSN 1042-7201. Artikkelin verkkoversio.
RF Porter et al: Selective cannabinoid 2 receptor agonists as potential therapeutic drugs for the treatment of endotoxin-induced uveitis. Molecules, 2019, 24. vsk, nro 18. PubMed:31540271. doi:10.3390/molecules24183338. ISSN 1420-3049. Artikkelin verkkoversio.
MM Aung et al: Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug and Alcohol Dependence, 2000, 60. vsk, nro 2, s. 133–140. PubMed:10940540. doi:10.1016/s0376-8716(99)00152-0. ISSN 0376-8716. Artikkelin verkkoversio.
JA Lile, TH Kelly, LR Hays: Separate and combined effects of the cannabinoid agonists nabilone and Δ9-THC in humans discriminating Δ9-THC. Drug and alcohol dependence, 2011, 116. vsk, nro 1-3, s. 86–92. PubMed:21227600. doi:10.1016/j.drugalcdep.2010.11.019. ISSN 0376-8716. Artikkelin verkkoversio.

ncbi.nlm.nih.gov

MR Elphick: The evolution and comparative neurobiology of endocannabinoid signalling. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367. vsk, nro 1607, s. 3201–3215. PubMed:23108540. doi:10.1098/rstb.2011.0394. ISSN 0962-8436. Artikkelin verkkoversio.
DI Abrams: Integrating cannabis into clinical cancer care. Current Oncology, 2016, 23. vsk, nro Suppl 2, s. S8–S14. PubMed:27022315. doi:10.3747/co.23.3099. ISSN 1198-0052. Artikkelin verkkoversio.
L Fattore, W Fratta: Beyond THC: the new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 2011, 5. vsk. PubMed:22007163. doi:10.3389/fnbeh.2011.00060. ISSN 1662-5153. Artikkelin verkkoversio.
S Zou, U Kumar: Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International Journal of Molecular Sciences, 2018, 19. vsk, nro 3. PubMed:29533978. doi:10.3390/ijms19030833. ISSN 1422-0067. Artikkelin verkkoversio.
S Basu, BN Dittel: Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunologic research, 2011, 51. vsk, nro 1, s. 26–38. PubMed:21626285. doi:10.1007/s12026-011-8210-5. ISSN 0257-277X. Artikkelin verkkoversio.
M Haney, MN Hill: Cannabis and cannabinoids: from synapse to society. Neuropsychopharmacology, 2018, 43. vsk, nro 1, s. 1–3. PubMed:29192667. doi:10.1038/npp.2017.255. ISSN 1740-634X. Artikkelin verkkoversio.
PH Reggio: Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Current medicinal chemistry, 2010, 17. vsk, nro 14, s. 1468–1486. PubMed:20166921. doi:10.2174/092986710790980005. ISSN 0929-8673. Artikkelin verkkoversio.
RG Pertwee: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 2008, 153. vsk, nro 2, s. 199–215. PubMed:17828291. doi:10.1038/sj.bjp.0707442. ISSN 0007-1188. Artikkelin verkkoversio.
C Hess et al: Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicology, 2016, 34. vsk, s. 329–343. PubMed:27429655. doi:10.1007/s11419-016-0320-2. ISSN 1860-8965. Artikkelin verkkoversio.
JA Marusich et al: Finding order in chemical chaos - continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology, 2018, 134. vsk, nro Pt A, s. 73–81. PubMed:29113898. doi:10.1016/j.neuropharm.2017.10.041. ISSN 0028-3908. Artikkelin verkkoversio.
RF Porter et al: Selective cannabinoid 2 receptor agonists as potential therapeutic drugs for the treatment of endotoxin-induced uveitis. Molecules, 2019, 24. vsk, nro 18. PubMed:31540271. doi:10.3390/molecules24183338. ISSN 1420-3049. Artikkelin verkkoversio.
JA Lile, TH Kelly, LR Hays: Separate and combined effects of the cannabinoid agonists nabilone and Δ9-THC in humans discriminating Δ9-THC. Drug and alcohol dependence, 2011, 116. vsk, nro 1-3, s. 86–92. PubMed:21227600. doi:10.1016/j.drugalcdep.2010.11.019. ISSN 0376-8716. Artikkelin verkkoversio.

sciencedirect.com

MM Aung et al: Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug and Alcohol Dependence, 2000, 60. vsk, nro 2, s. 133–140. PubMed:10940540. doi:10.1016/s0376-8716(99)00152-0. ISSN 0376-8716. Artikkelin verkkoversio.

semanticscholar.org

pdfs.semanticscholar.org

SMR Gurney et al: Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Science Review, 2014, 26. vsk, nro 1, s. 53–78. PubMed:26226970. ISSN 1042-7201. Artikkelin verkkoversio.

tandfonline.com

DR Janero, A Makriyannis: Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs, 2009, 14. vsk, nro 1, s. 43–65. PubMed:19249987. doi:10.1517/14728210902736568. ISSN 1744-7623. Artikkelin verkkoversio.

wiley.com

onlinelibrary.wiley.com

I Canazza et al: Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. Human Psychopharmacology, 2017, 32. vsk, nro 3. PubMed:28597570. doi:10.1002/hup.2601. ISSN 1099-1077. Artikkelin verkkoversio.

worldcat.org

MR Elphick: The evolution and comparative neurobiology of endocannabinoid signalling. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367. vsk, nro 1607, s. 3201–3215. PubMed:23108540. doi:10.1098/rstb.2011.0394. ISSN 0962-8436. Artikkelin verkkoversio.
DI Abrams: Integrating cannabis into clinical cancer care. Current Oncology, 2016, 23. vsk, nro Suppl 2, s. S8–S14. PubMed:27022315. doi:10.3747/co.23.3099. ISSN 1198-0052. Artikkelin verkkoversio.
L Fattore, W Fratta: Beyond THC: the new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 2011, 5. vsk. PubMed:22007163. doi:10.3389/fnbeh.2011.00060. ISSN 1662-5153. Artikkelin verkkoversio.
DR Janero, A Makriyannis: Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs, 2009, 14. vsk, nro 1, s. 43–65. PubMed:19249987. doi:10.1517/14728210902736568. ISSN 1744-7623. Artikkelin verkkoversio.
S Zou, U Kumar: Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International Journal of Molecular Sciences, 2018, 19. vsk, nro 3. PubMed:29533978. doi:10.3390/ijms19030833. ISSN 1422-0067. Artikkelin verkkoversio.
S Basu, BN Dittel: Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunologic research, 2011, 51. vsk, nro 1, s. 26–38. PubMed:21626285. doi:10.1007/s12026-011-8210-5. ISSN 0257-277X. Artikkelin verkkoversio.
ES Onaivi et al: Cannabinoid receptor gene variations in drug addiction and neuropsychiatric disorders. Journal of Drug and Alcohol Research, 2013, 2. vsk, s. 1–11. doi:10.4303/jdar/235714. ISSN 2090-8334. Artikkelin verkkoversio.
M Haney, MN Hill: Cannabis and cannabinoids: from synapse to society. Neuropsychopharmacology, 2018, 43. vsk, nro 1, s. 1–3. PubMed:29192667. doi:10.1038/npp.2017.255. ISSN 1740-634X. Artikkelin verkkoversio.
PH Reggio: Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Current medicinal chemistry, 2010, 17. vsk, nro 14, s. 1468–1486. PubMed:20166921. doi:10.2174/092986710790980005. ISSN 0929-8673. Artikkelin verkkoversio.
RG Pertwee: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 2008, 153. vsk, nro 2, s. 199–215. PubMed:17828291. doi:10.1038/sj.bjp.0707442. ISSN 0007-1188. Artikkelin verkkoversio.
C Hess et al: Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicology, 2016, 34. vsk, s. 329–343. PubMed:27429655. doi:10.1007/s11419-016-0320-2. ISSN 1860-8965. Artikkelin verkkoversio.
I Canazza et al: Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. Human Psychopharmacology, 2017, 32. vsk, nro 3. PubMed:28597570. doi:10.1002/hup.2601. ISSN 1099-1077. Artikkelin verkkoversio.
JA Marusich et al: Finding order in chemical chaos - continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology, 2018, 134. vsk, nro Pt A, s. 73–81. PubMed:29113898. doi:10.1016/j.neuropharm.2017.10.041. ISSN 0028-3908. Artikkelin verkkoversio.
SMR Gurney et al: Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Science Review, 2014, 26. vsk, nro 1, s. 53–78. PubMed:26226970. ISSN 1042-7201. Artikkelin verkkoversio.
RF Porter et al: Selective cannabinoid 2 receptor agonists as potential therapeutic drugs for the treatment of endotoxin-induced uveitis. Molecules, 2019, 24. vsk, nro 18. PubMed:31540271. doi:10.3390/molecules24183338. ISSN 1420-3049. Artikkelin verkkoversio.
MM Aung et al: Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug and Alcohol Dependence, 2000, 60. vsk, nro 2, s. 133–140. PubMed:10940540. doi:10.1016/s0376-8716(99)00152-0. ISSN 0376-8716. Artikkelin verkkoversio.
JA Lile, TH Kelly, LR Hays: Separate and combined effects of the cannabinoid agonists nabilone and Δ9-THC in humans discriminating Δ9-THC. Drug and alcohol dependence, 2011, 116. vsk, nro 1-3, s. 86–92. PubMed:21227600. doi:10.1016/j.drugalcdep.2010.11.019. ISSN 0376-8716. Artikkelin verkkoversio.